Oncology Business Management | Specialty

FDA Approves Eltrombopag for Severe Aplastic Anemia

August 26th 2014

The FDA has approved eltrombopag as a treatment for patients with severe aplastic anemia following an insufficient response to immunosuppressive therapy.

Increased Medicaid Payments for Office Visits Results in More Screening for Cancer

August 26th 2014

Medicaid patients in states that pay more for office visits had an increased likelihood of being screened for cancer, according to results of a study published in CANCER.

Report Identifies Shortfalls in Medicare Accountability Model

August 25th 2014

How much physicians get paid is increasingly determined by a payment formula that penalizes doctors whose patients are more expensive-even when those higher costs stem from services that other doctors perform says a new report from the Center for Healthcare Quality and Payment Reform.

COME HOME Program Set to Save $33.5M Over 3 Years

August 25th 2014

In an interview with Oncology Business Management, Barbara L. McAneny, MD, explains how the program will address fragmented care, suboptimal outcomes, high costs, and patient dissatisfaction.

Hospitals Snap Up Practices Under 340B Drug Program

August 20th 2014

A federal program originally meant to require drug manufacturers to provide significant discounts for outpatient drugs is increasingly being used by hospitals to acquire private oncology practices.

Using Technology to Improve Patient Fee Collection Rates

August 19th 2014

Although the Affordable Care Act (ACA) made accessibility to health insurance easier, consumers are finding themselves shouldering greater out-of-pocket costs in the form of copayments and deductibles for the care that they receive. Physicians are also feeling the need to collect more fees from more of their patients.

Medicare to Pay Docs for Chronic Care Coordination

August 18th 2014

Starting in January 2015, Medicare will begin paying physicians for the care coordination they provide beneficiaries with chronic conditions.

FDA Approves Bevacizumab for Advanced Cervical Cancer

August 14th 2014

The FDA has approved bevacizumab in combination with paclitaxel and cisplatin or paclitaxel and topotecan as a treatment for patients with persistent, recurrent, or metastatic cervical cancer.

Tripathy Offers Perspective on HER2-Positive Breast Cancer

August 13th 2014

The ever-evolving treatment landscape for patients with HER2-positive breast cancer leaves several questions unanswered regarding therapeutic sequences and whether an optimal standard of care exists.

FDA Approves First DNA-Based CRC Screening Tool

August 12th 2014

The FDA has approved the noninvasive stool-based DNA test Cologuard for the detection of colorectal cancer or cancer precursors in asymptomatic patients at average risk.

Two-Part Series to Explore Use of Biomarkers in GU Cancer Treatment

August 12th 2014

When it comes to the personalized treatment of genitourinary cancers, biomarkers hold an immense amount of promise. Already, there are predictive and prognostic tools available to urologists.

Glycans Emerge as Promising Biomarkers for Early Detection of Many Cancer Types

July 30th 2014

For many years, we in the medical and research communities have tried to use proteins and DNA fragments as disease markers to find cancer early.

Change to Reimbursement Is Coming! Do We Believe It and Are We Ready?

July 29th 2014

I find it striking that some of my colleagues believe the changes in reimbursement that are under consideration in oncology care delivery will be one of many trends that rises dramatically from the ever present background noise only to later fade into oblivion

FDA Approves Idelalisib for CLL, SLL, and Follicular Lymphoma

July 23rd 2014

The FDA has approved idelalisib in combination with rituximab for patients with high-risk relapsed or refractory CLL and as a single-agent for two types of iNHL.

Bevacizumab Receives Priority Review in Ovarian Cancer

July 22nd 2014

The FDA has assigned a priority review designation to bevacizumab (Avastin) in combination with chemotherapy for patients with recurrent platinum-resistant ovarian cancer.

Amid Calls for Standardization, Oncology Medical Homes Grow

July 22nd 2014

For the past 10 years, John Sprandio, MD, has been standardizing care delivery processes for cancer patients.

Immunotherapy Combination Receives Breakthrough Designation for Pancreatic Cancer

July 21st 2014

The combination of the immunotherapy CRS-207 and the vaccine GVAX Pancreas has received a breakthrough therapy designation from the FDA for its potential as a treatment for patients with metastatic pancreatic cancer.

ASCO 2014: Gearing Up for More Changes

July 21st 2014

The ASCO annual meeting is always a time of excitement for the nearly 30,000 clinicians and scientists who gather every year to see "what's new."

Future Immunotherapy Strategies in Cancer

July 18th 2014

Checkpoint Inhibitors Under Exploration in RCC

July 18th 2014